

Lumify™ (brimonidine) – New over-the-counter drug approval

- On December 22, 2017, [Bausch and Lomb announced the FDA approval](#) of [Lumify \(brimonidine\) 0.025% ophthalmic solution](#), to relieve redness of the eye due to minor eye irritations.
- Lumify is the first over-the-counter (OTC) eye drop developed with low-dose brimonidine.
- Brimonidine is also available as ophthalmic prescription medications in higher doses as follows: [0.15% solution](#), [0.2% solution](#), [Alphagan® P 0.1% and 0.15% solution](#), 0.2% suspension in combination with brinzolamide 1% ([Simbrinza®](#)), and 0.2% solution in combination with timolol 0.5% ([Combigan®](#)).
 - These prescription strength brimonidine products are indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
- Warnings of Lumify include for external use only; do not use if solution changes color or becomes cloudy; and stop use and consult a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, condition worsens or persists for more than 3 days.
- The recommended dosage of Lumify in adults and children ≥ 5 years is one drop into the affected eye(s) every 6 -8 hours.
 - Lumify should not be used more than four times daily.
 - Contact lenses should be removed before instilling Lumify. Lenses may be re-inserted 10 minutes after instilling Lumify.
 - If other ophthalmic products are being used, wait 5 minutes between using each product.
- Bausch and Lomb plans to launch Lumify in the second quarter of 2018.